The Effect of Silymarin on Oral Nifedipine Pharmacokinetics

Abstract

Silibinin, the main component of silymarin (a milk thistle extract used for treatment of liver injury), has been shown to inhibit CYP3A4 in human liver microsomes. The present study was conducted to examine whether inhibition of CYP3A4 by silymarin is also present in vivo. Immediate release nifedipine (10 mg) was administered as a CYP3A4 test drug either alone or with co-administration of silymarin (280 mg administered 10 hours and 1.5 hours prior to the administration of nifedipine) to 16 healthy male volunteers (mean age 27 years, mean body weight 77 kg). Nifedipine and silibinin concentrations were quantified by HPLC, heart rate and blood pressure were monitored for safety reasons. Pharmacokinetic parameters were calculated by non-compartmental methods, and the potential interaction by silymarin was handled as an equivalence problem. We found that nifedipine AUC was 1.13-fold higher (90 % CI, 0.97- to 1.32-fold) in the silymarin period, C_max values were 0.70-fold (90 % CI, 0.39- to 1.27-fold) of those of the reference period, with a trend to delayed absorption in the silymarin period. Intraindividual variability especially for C_max (intrasubject CV 120 %) was unexpectedly high. There was no meaningful effect on hemodynamic parameters. In conclusion, our data suggest that co-administration of silymarin does not considerably change the extent of absorption or metabolism of nifedipine but may decrease the absorption rate. Silymarin thus is not a potent CYP3A4 inhibitor in vivo.

Key words:

Silybum marianum (L.) Gaertn. - Asteraceae - silymarin - silibinin - milk thistle extract - nifedipine - CYP3A4 - drug-drug interaction

References

• 1 Leng-Peschlow E, Strenge-Hesse A. Die Mariendistel (Sylibum marianum) und Silymarin als Lebertherapeutikum.  Z Phytother. 1991;  12 162-74.
• 2 Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease.  Am J Gastroenterol. 1998;  93 139-43.
• 3 Gazak R, Walterova D, Kren V. Silybin and silymarin - new and emerging applications in medicine.  Curr Med Chem. 2007;  14 315-38.
• 4 Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin.  Forsch Komplementarmed. 2007;  14 70-80.
• 5 Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Bocker R H, Beckurts K T, Lang W. et al . Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes.  Pharmacol Toxicol. 2000;  86 250-6.
• 6 Böcker R H, Guengerich F P. Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450.  J Med Chem. 1986;  29 1596-603.
• 7 Sridar C, Goosen T C, Kent U M, Williams J A, Hollenberg P F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases.  Drug Metab Dispos. 2004;  32 587-94.
• 8 Zuber R, Modriansky M, Dvorak Z, Rohovsky P, Ulrichova J, Simanek V. et al . Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities.  Phytother Res. 2002;  16 632-8.
• 9 Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay.  Int J Clin Pharmacol Ther Toxicol. 1992;  30 134-8.
• 10 Lorenz D, Lucker P W, Mennicke W H, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile.  Methods Find Exp Clin Pharmacol. 1984;  6 655-61.
• 11 Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients.  Arzneimittelforschung. 1992;  42 964-8.
• 12 Schandalik R, Perucca E. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction.  Drugs Exp Clin Res. 1994;  20 37-42.
• 13 Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.  Drug Saf. 1998;  18 251-72.
• 14 Watkins P B. Noninvasive tests of CYP3A enzymes.  Pharmacogenetics. 1994;  4 171-84.
• 15 Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the ”cocktail” approach.  Clin Pharmacol Ther. 2007;  81 270-83.
• 16 Shen D D, Kunze K L, Thummel K E. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.  Adv Drug Deliv Rev. 1997;  27 99-127.
• 17 Galetin A, Ito K, Hallifax D, Houston J B. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.  J Pharmacol Exp Ther. 2005;  314 180-90.
• 18 Bailey D G, Spence J D, Munoz C, Arnold J M. Interaction of citrus juices with felodipine and nifedipine.  Lancet. 1991;  337 268-9.
• 19 Venkatakrishnan K, von Moltke L L, Greenblatt D J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.  Clin Pharmacokinet. 2000;  38 111-80.
• 20 Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A. et al . Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms.  J Clin Pharm Ther. 2005;  30 153-8.
• 21 Rickling B, Hans B, Kramarczyk R, Krumbiegel G, Weyhenmeyer R. Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection.  J Chromatogr B Biomed Appl. 1995;  670 267-77.
• 22 Steinijans V W, Hartmann M, Huber R, Radtke H W. Lack of pharmacokinetic interaction as an equivalence problem.  Int J Clin Pharmacol Ther Toxicol. 1991;  29 323-8.
• 23 Diletti E, Hauschke D, Steinijans V W. Sample size determination for bioequivalence assessment by means of confidence intervals.  Int J Clin Pharmacol Ther Toxicol. 1991;  29 1-8.
• 24 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Carrier J. et al . In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.  Clin Pharmacol Ther. 2004;  76 428-40.
• 25 van Erp N P, Baker S D, Zhao M, Rudek M A, Guchelaar H J, Nortier J W. et al . Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.  Clin Cancer Res. 2005;  11 7800-6.
• 26 Niopas I, Daftsios A C, Xanthakis I, Nikolaidis N. Relative bioavailability study of two nifedipine tablet formulations in healthy male volunteers.  Int J Clin Pharmacol Ther. 2000;  38 309-14.
• 27 Rawashdeh N M, Battah A H, Irshaid Y M, al-Qato M K. Comparative pharmacokinetics of two nifedipine products in capsule form following single oral administration in healthy volunteers.  Eur J Drug Metab Pharmacokinet. 1997;  22 259-64.
• 28 Reitberg D P, Love S J, Quercia G T, Zinny M A. Effect of food on nifedipine pharmacokinetics.  Clin Pharmacol Ther. 1987;  42 72-5.
• 29 Bode H, Brendel E, Ahr G, Fuhr U, Harder S, Staib A H. Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine.  Eur J Clin Pharmacol. 1996;  50 195-201.
• 30 Renwick A G, Ahsan C H, Challenor V F, Daniels R, Macklin B S, Waller D G. et al . The influence of posture on the pharmacokinetics of orally administered nifedipine.  Br J Clin Pharmacol. 1992;  34 332-6.
• 31 Rumble R H, Roberts M S, Denton M J. Effects of posture and sleep on the pharmacokinetics of paracetamol (acetaminophen) and its metabolites.  Clin Pharmacokinet. 1991;  20 167-73.
• 32 Di Carlo G, Autore G, Izzo A A, Maiolino P, Mascolo N, Viola P. et al . Inhibition of intestinal motility and secretion by flavonoids in mice and rats: structure-activity relationships.  J Pharm Pharmacol. 1993;  45 1054-9.
• 33 Mahagita C, Grassl S M, Piyachaturawat P, Ballatori N. Human organic anion transporter 1B1 (OATP1B1/OATP-C) and 1B3 (OATP1B3/OATP-8) function as bidirectional carriers and do not mediate GSH-bile acid co-transport. Am J Physiol Gastrointest Liver Physiol 2007: in press.
• 34 Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes.  Toxicol Sci. 2006;  91 140-9.